Featured Research

from universities, journals, and other organizations

Higher than normal levels of Vitamin B12 may indicate cancer risk

Date:
November 18, 2013
Source:
Journal of the National Cancer Institute
Summary:
Vitamin B12 (cobalamin [Cbl]) is essential for maintaining healthy bodily function, but higher than normal levels (reference range 200-600 pmol/L) may indicate that a patient is at risk of developing certain cancers, according to a study published. Previous studies had suggested an association between high Cbl levels and specific cancers.

Vitamin B12 (cobalamin [Cbl]) is essential for maintaining healthy bodily function but higher than normal levels (reference range 200-600 pmol/L) may indicate that a patient is at risk of developing certain cancers, according to a study published November 18 in the Journal of the National Cancer Institute. Previous studies had suggested an association between high Cbl levels and specific cancers.

To assess the association between high Cbl levels and risk of cancer of any type, Johan Arendt, BSc, of the Department of Clinical Epidemiology and the Department of Clinical Biochemistry of Aarhus University Hospital in Denmark, and colleagues used Danish Medical registries to review the records of 333,667 patients without cancer who had been referred for Cbl testing and to estimate the incidence of cancer in this population from 1998 to 2010.

The researchers excluded patients who had a cancer diagnosis before the date of plasma measurement and those who were receiving Cbl therapy. They found that the risk of cancer overall increased with higher Cbl levels, especially during the first year after measurement and for those with levels > 800pmol/L. They also found that after five years of follow-up, the risk for hematological and alcohol and smoking-related cancers remained high for those with levels > 800pmol/L.

The authors conclude that "…high plasma Cbl levels increased the risk of subsequently diagnosed cancer, mostly within the first year of follow-up." However, Arendt et al. note that high plasma Cbl levels are probably not related to normal Vitamin B12 intake because consumption of Cbl containing foods or supplements do not increase plasma Cbl levels substantially. Rather, high Cbl levels may result from some unknown malignant process.


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. F. B. Arendt, L. Pedersen, E. Nexo, H. T. Sorensen. Elevated Plasma Vitamin B12 Levels as a Marker for Cancer: A Population-Based Cohort Study. JNCI Journal of the National Cancer Institute, 2013; DOI: 10.1093/jnci/djt315

Cite This Page:

Journal of the National Cancer Institute. "Higher than normal levels of Vitamin B12 may indicate cancer risk." ScienceDaily. ScienceDaily, 18 November 2013. <www.sciencedaily.com/releases/2013/11/131118162805.htm>.
Journal of the National Cancer Institute. (2013, November 18). Higher than normal levels of Vitamin B12 may indicate cancer risk. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2013/11/131118162805.htm
Journal of the National Cancer Institute. "Higher than normal levels of Vitamin B12 may indicate cancer risk." ScienceDaily. www.sciencedaily.com/releases/2013/11/131118162805.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins